More top hospitals aren’t offering Aduhelm

STAT has identified another 15 major, university-affiliated hospitals that aren't offering the controversial new Alzheimer's drug Aduhelm. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     ‘It’s almost negligible’: More top hospitals aren't offering controversial Alzheimer's drug Aduhelm By Nicholas Florko Alex Hogan/STAT Major health care systems made it clear almost immediately after Aduhelm was approved that they wouldn’t offer the new therapy, citing a lack of convincing evidence that the drug actually helps treat Alzheimer’s disease. Now, STAT has identified another 15 university-affiliated hospitals that aren’t offering the drug. Read More Sponsor content by AMGEN INFLAMMATION How does a molecule get from the lab to patients? The discovery and development journey Developing medicines that will help patients in need is at the heart of what Amgen does, says David Reese, Executive Vice President, Research and Development at Amgen. “That’s why we’re here, it’s why I come to work every day.” But what exactly does it take to get there? Hear from David, scientists, and researchers about what it takes to bring a molecule from discovery to development. More great reads from STAT this week ‘A black box’: Emergency medics remain locked out of electronic health records By Marion Renault Doctors have an arsenal of Covid-19 treatments, but setbacks and shortages are undercutting options By Andrew Joseph A WHO official weighs in on Covid, vaccines, and mistakes that were made By Helen Branswell Why the conviction of Elizabeth Holmes hinged on defrauding Theranos investors, not patients By Casey Ross Robert Califf is a fervent believer in data. At the FDA, will that be enough? By Matthew Herper What racism in medicine takes from us By Jennifer Adaeze Okwerekwu Chatbots, surveys, and texts: Telehealth companies cut costs by reimagining the front desk By Mohana Ravindranath Texas is trying to create the next research triangle for biotech. Will it work? By Maddie Bender 3 CRISPR editing innovations to watch in 2022 By Megan Molteni Pushback to Covid-19 vaccines remains stubbornly high among white evangelicals By Joanne Silberner Saturday, January 8, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser